Guhan Medicine: Announcement on Purchasing Directors and Senior Management Liability Insurance
Securities code: 000590 Securities abbreviation: Guhan Medicine Announcement number: 2026-015
Guhan Pharmaceutical Group Co., Ltd.
Announcement on Purchasing Directors and Senior Management Liability Insurance
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
In order to further improve the risk management system of Guhan Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company"), reduce the company's operational risks, protect the rights and interests of the company and investors, and promote the company's directors and senior managers to fully exercise their rights and perform their duties, the company plans to purchase directors and senior managers' liability insurance (hereinafter referred to as "Dong Gao Liability Insurance") for the company and all directors and senior managers.
The company held the eighth meeting of the tenth board of directors on March 29, 2026, and agreed to submit the "Proposal on Purchasing Liability Insurance for Directors and Senior Management Personnel" to the company's shareholders' meeting for review (all directors of the company, as insured persons, abstained from voting when considering this matter based on the principle of prudence).
1. The company’s specific plan to purchase Dong Gao liability insurance
(1) Insured person: Guhan Pharmaceutical Group Co., Ltd.
(2) Insured: directors, senior managers and other relevant responsible personnel of the company and its subsidiaries (specifically subject to the scope determined through negotiation with the insurance company)
(3) Compensation limit: no more than RMB 10 million (the specific amount shall be subject to the final signed insurance contract)
(4) Insurance fee: no more than RMB 50,000 per year (the specific amount is ultimately based on the insurance company’s quotation and negotiation, and is subject to the final signed insurance contract)
(5) Insurance period: 12 months (the specific start and end time shall be subject to the final signed insurance contract, and the insurance can be renewed or re-insured every year)
In order to improve the efficiency of decision-making, the board of directors requested the company's shareholders to authorize the board of directors, and the board of directors, to authorize the company's management to handle matters related to the purchase of Dong-Gao liability insurance within the above authority (including but not limited to determining the insurance company; determining the compensation limit, insurance premium and other insurance terms; signing relevant legal documents and handling other matters related to insurance, etc.), as well as handling renewal or re-insurance and other related matters on or before the expiration of the subsequent Dong-Gao liability insurance contract, without exceeding the scope of the aforementioned insurance plan.
2. The impact of this purchase of Donggao liability insurance on listed companies
The purchase of Dong Gao liability insurance complies with the requirements of the Company Law, the Code of Governance of Listed Companies and other relevant systems, and can provide effective protection for the company's directors and senior managers to perform their duties in daily production and operations, thereby increasing the enthusiasm of the management team for operations and promoting the company's high-quality development.
The estimated cost of purchasing Dong Gao liability insurance this time is within the reasonable range of the market, will not have a significant impact on the company's financial status, and will not harm the interests of the company and shareholders, especially small and medium-sized shareholders. This proposal needs to be submitted to the company's shareholders' meeting for review.
Announcement is hereby made.
Board of Directors of Guhan Pharmaceutical Group Co., Ltd.
March 31, 2026